Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study

Wen, Wang; Liu, Yanmei; Yu, Chuan; Tan, Jing; Xiong, Weiyi; Dong, Diansheng; Li, Sheyu; Zhang, Rui; Li, Jijie; Wu, Yuzhang; Zong, Zhiyong; Su, Naichuan; Zou, Kang; Wu, Guizhi; Sun, Xin

doi:10.1080/14740338.2020.1713090

Cited by 40 publications

(39 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Safety, especially in the context of coagulopathy, is a serious concern for clinicians prescribing cefoperazonesulbactam. [24][25][26] No significant difference in pre-and post-treatment INR was observed in 30 patients receiving cefoperazone, but most of the patients did not have the assessment of coagulation disorder in this study. According to retrospective review of medical chart, no patients receiving cefoperazone-sulbactam had significant bleeding.…”

Section: Discussionmentioning

confidence: 55%

Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

Chen

et al. 2021

IDR

View full text Add to dashboard Cite

Objective The aim of this study was to compare the usefulness of cefoperazone-sulbactam and that of piperacillin-tazobactam in the treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Methods This retrospective study included the adult patients receiving cefoperazone-sulbactam or piperacillin-tazobactam against HAP/VAP in nine hospitals in Taiwan from March 1, 2018 to May 30, 2019. Primary outcome was clinical cure rate. Results A total of 410 patients were enrolled. Among them, 209 patients received cefoperazone-sulbactam and 201 patients received piperacillin-tazobactam. Overall, cefoperazone-sulbactam group had similar distribution of age, sex, or SOFA scores as piperacillin-tazobactam group. However, cefoperazone-sulbactam had higher comorbidity score and disease severity than piperacillin-tazobactam group (Charlson score: 6.5 ± 2.9 vs 5.7 ± 2.7, p < 0.001; APACHE II score: 21.4 ± 6.2 vs 19.3 ± 6.0, p = 0.002). Regarding clinical outcomes, no significant difference in clinical cure and failure rates was observed between cefoperazone-sulbactam and piperacillin-tazobactam group (clinical cure rate: 80.9% vs 80.1% and clinical failure rate: 17.2% vs 18.4%, p = 0.943). Moreover, no significant difference in clinical effectiveness and ineffectiveness rates was observed between cefoperazone-sulbactam and piperacillin-tazobactam group (clinical effective rate: 80.9% vs 80.6% and clinical ineffective rate: 17.7% vs 18.9%, p = 0.711). The all-cause mortality rates of the cefoperazone-sulbactam and piperacillin-tazobactam groups were similar (23.9% vs 20.9%, p = 0.48). After adjustment of Charlson score and APACHE II score, the similarities in these clinical outcomes did not change in overall patients and patients with HAP or VAP. Conclusion For treating adult patients with nosocomial pneumonia, cefoperazone-sulbactam was as effective as piperacillin-tazobactam.

show abstract

Section: Discussionmentioning

confidence: 55%

Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

Chen

et al. 2021

IDR

View full text Add to dashboard Cite

show abstract

“…The primary outcomes were coagulation disorders and any bleeding. The coagulation disorders were defined as an increase by 25% from the baseline of either PT, APTT or TT 2 . If any bleeding happened, assessment of the Naranjo adverse drug reaction probability scale was used to determine whether the bleeding was caused by ceftazidime or latamoxef.…”

Section: Methodsmentioning

confidence: 99%

“…Latamoxef has an N‐methylthiotetrazole (NMTT) side chain which was thought to be a key structure to induce vitamin K deficiency, hypoprothrombinemia, thrombocytopenia and bleeding 1 . Cefoperazone, which also carries an NMTT structure, was linked with a higher risk of hypoprothrombinemia, with the reported incidence ranging 4%–68% 2 . Several researchers noticed that latamoxef could induce prolonged prothrombin time (PT) or activated partial thromboplastin time (APTT) 1,3 .…”

Section: What Is Known and Objectivementioning

confidence: 99%

See 1 more Smart Citation

Latamoxef‐induced coagulation disorders: Incidence and risk factors

et al. 2021

View full text Add to dashboard Cite

Latamoxef is a broad-spectrum oxacephem antibiotic widely used in moderate to severe infections such as respiratory, intra-abdominal or urinary tract infections. Latamoxef has an N-methylthiotetrazole (NMTT) side chain which was thought to be a key structure to induce vitamin K deficiency, hypoprothrombinemia, thrombocytopenia and bleeding. 1 Cefoperazone, which also carries an NMTT structure, was linked with a higher risk of hypoprothrombinemia, with the reported incidence ranging 4%-68%. 2 Several researchers noticed that latamoxef could induce prolonged prothrombin time (PT) or activated partial thromboplastin time (APTT). 1,3 However, there were very few Asian patients till now. Zhu et al reported two cases of severe coagulation disorder induced by latamoxef. 4 In this study, we initiated a retrospective cohort study and included 162 Chinese patients with different conditions, thus to give insight into the effects of latamoxef on coagulation function. | ME THODS | Patient selectionA retrospective cohort study was conducted and patients treated with ceftazidime or latamoxef at Second Affiliated Hospital of Xi'an Jiaotong University between 1 January 2018 and 31 December 2018 were included. Exclusion criteria included: Patients were experiencing episodes of haematemesis; patients with sepsis, liver

show abstract

“…The information about TCM use was collected from ICU prescriptions which were documented in the EMRs. We established drug dictionary using drug codes provided by the hospital, which were previously validated [ 12 ] and contained information regarding drug name, route of administration, usage, and type of TCM.…”

Section: Main Textmentioning

confidence: 99%

Utilization of traditional Chinese medicine in the intensive care unit

Zhang

Wang

et al. 2021

Chin Med

Self Cite

View full text Add to dashboard Cite

Previous studies showed that traditional Chinese medicine (TCM) may be effective for patients with critical conditions. However, the extent to which TCM is used in intensive care units (ICUs) remains less investigated. This study aimed to investigate the utilization of TCM among ICU patients. Using a cross-sectional study design, we examined the use of TCMs among ICU patients. The data were from a well-established ICU registry from a large teaching hospital in west China. Our study found that TCM was widely used among ICU, in particular TCM injections and oral liquids. The use of TCM often differed by ICUs, and TCM injections and oral liquids were mostly used in neurological ICU, while Chinese herbal medicines (CHMs) were often used in general ICU. The use of TCM was also highly associated with patient characteristics. Patients with pancreatitis were administered with most TCM, patients with cerebrovascular disease with most TCM injections and those with chronic renal failure with most oral liquids. Future efforts should include generation of high-quality evidence guidelines about clinical effects of TCM interventions among ICU patients.

show abstract

Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study

Cited by 40 publications

References 23 publications

Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

Latamoxef‐induced coagulation disorders: Incidence and risk factors

Utilization of traditional Chinese medicine in the intensive care unit

Contact Info

Product

Resources

About